Apexigen

Apexigen is a San Carlos, California-based clinical-stage biopharmaceutical company that discovers and develops humanized monoclonal antibody therapeutics for oncology applications. The enterprise utilizes its proprietary APXiMAB platform to generate immuno-oncology treatments, including its lead candidate sotigalimab, which is designed to activate the immune system against solid tumors. Before merging with SPAC Brookline Capital Acquisition Corp to enter the public markets in 2022, the business raised over $150 million in private venture funding, including a $73 million Series C round, from backers like 3E Bioventures Capital. Operating with an estimated 11 to 50 employees, the firm advanced its Phase 2 clinical trials through strategic partnerships with institutions such as UCSF before being acquired by Pyxis Oncology for approximately $10.7 million in August 2023. Apexigen was founded as a spin-out from Epitomics in 2010 by Xiaodong Yang.